News & Updates

Among treatment-naïve patients with HIV-1* infection, initial treatment combination with doravirine and islatravir (DOR/ISL) was noninferior in achieving virologic suppression (HIV-1 RNA <50 copies/mL) at week 48 compared with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), according to a trial presented at IAS 2023.

Nightly administration of atropine 0.01% eye drops does little to slow myopia progression or axial elongation in a cohort of school-aged children in the US who have low-to-moderate myopia, as shown in a study.

Misoprostol alone appears to be safe and effective for termination of first trimester pregnancy and can be used if mifepristone is unavailable or inaccessible, according to a study.

In women with heavy menstrual bleeding, treatment with levonorgestrel intrauterine system is as good as combined oral contraceptives, with both strategies improving bleeding-related quality of life, as reported in a study.

New immune-related adverse events (irAEs) start to appear more than 6 months following completion of selective immunosuppressive therapy (SIT) agents, such as infliximab and vedolizumab, for initial colitis events, reports a study.

In conjunction with the 42nd International Symposium on Intensive Care and Emergency Medicine (ISICEM), Pfizer sponsored a symposium addressing the complex challenges of managing invasive mould disease (IMD) in the intensive care unit (ICU), emphasizing the importance of a proactive mindset among intensivists. Using a real-life patient case study, Dr Paula Ramirez from La Fe University and Polytechnic Hospital, Valencia, Spain highlighted the significance of early suspicion, swift diagnosis, and timely treatment in critically ill patients with IMD. Professor Gennaro De Pascale from the Catholic University of the Sacred Heart, Rome, Italy discussed effective management strategies and the clinical evidence for various antifungals in treating IMD in critically ill patients.